Amrutanjan Health Care Limited — PPTs, 13-08-2025: Investor Presentation

**1. Financial Highlights:**

AHCL's Q1 FY26 saw Net Sales up 12.31% to ₹94.05 Cr. PBT surged 77.80% to ₹11.29 Cr, PAT jumped 79.87% to ₹8.31 Cr. Pain Management grew 26%, Comfy 11%. Rehydration sales declined 17%. Management aims for 13% operating profit margin (from 11.44%).

**2. Strategic Initiatives & Growth Drivers:**

Focus on boosting Amrutanjan balm household penetration via consumer engagement. Expanding sales/distribution networks, including Pharma Super Stockists, is active. Operational efficiency and Ecom/Quick Commerce channel growth are core priorities.

**3. Business Developments:**

Strong product performance observed in Pain Management and Congestion lines. Comfy's XL variant and value packs also boosted Women's Hygiene. Sales infrastructure improved with increased stockist network and productivity gains.

**4. Market Position & Competitive Advantage:**

Amrutanjan's Pain Management volume growth significantly outpaced competitors. It holds a leading share in the growing Roll-on category, validated by new market entrants.

**5. Investor Implications:**

The quarter shows positive growth potential, driven by robust Pain Management and strategic market expansion. Key watch areas: margin expansion and Rehydration segment recovery.